<DOC>
	<DOCNO>NCT00630058</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics , HCV RNA kinetics , viral characteristic administration two arm MP-424 combination Peginterferon Alfa 2b ( PEG-IFN-a-2b ) Ribavirin ( RBV ) patient chronic hepatitis C .</brief_summary>
	<brief_title>A Phase 1 Study MP-424 , Peginterferon Alfa 2b , Ribavirin Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Patients diagnose genotype 1b chronic hepatitis C Patients diagnose decompensated cirrhosis Patients diagnose positive HBs antigen test</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Telaprevir</keyword>
</DOC>